Skip to content

Targeting the Primary Visual Cortex–Hippocampus Circuit With Transcranial Magnetic Stimulation to Improve Cognition in Bipolar Disorder: A Randomized Controlled Trial

Targeting the Primary Visual Cortex–Hippocampus Circuit With Transcranial Magnetic Stimulation to Improve Cognition in Bipolar Disorder: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116589
Enrollment
Unknown
Registered
2026-01-12
Start date
2026-01-12
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive deficit

Interventions

Control group:Sham TMS group: Undergo the same procedure as Group A, but use a sham coil that produces a similar sound without delivering a magnetic field, to maintain blinding.
Intervention group:True TMS group: Receive robot-assisted, neuronavigated true transcranial magnetic stimulation (TMS) targeting the point of strongest fiber connectivity between the primary visual co

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.Age between 18 and 45 years; 2.Right-handed; 3.Meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for bipolar disorder and are currently in a euthymic/stable remission phase; 24-item Hamilton Depression Rating Scale (HAMD-24) score < 8; 4.Young Mania Rating Scale (YMRS) score <= 7; 5.The participant and his/her legal guardian are willing to comply with the treatment procedures and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1.Diagnosis of another primary psychiatric disorder judged by the investigators to be the predominant condition, with functional impairment exceeding that attributable to bipolar disorder; 2.Comorbid psychiatric disorders, including obsessive–compulsive disorder, personality disorders, anxiety spectrum disorders, intellectual disability, or substance use (dependence/abuse); 3.Inability to complete self-report symptom rating scales or the CANTAB cognitive assessment; 4.Prominent suicidal ideation (item 3 of the 24-item Hamilton Depression Rating Scale [HAMD-24] >= 2); 5.A clear risk of self-harm or harm to others; 6.History of severe physical illness or other medical conditions that may affect the central nervous system; 7.Neurological disorders or risk factors for seizures, such as a history of intracranial disease, head injury, abnormal electroencephalogram (EEG) findings, magnetic resonance imaging (MRI) evidence of structural brain abnormalities, or a family history of epilepsy; 8.Contraindications to MRI or transcranial magnetic stimulation, such as the presence of metallic or electronic implants (e.g., intracranial metallic foreign bodies, cochlear implants, cardiac pacemakers, vascular stents); 9.Receipt of electroconvulsive therapy (ECT) within 6 months prior to study enrollment; 10.Currently undergoing transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neuromodulatory interventions; 11.Pregnant or breastfeeding women, and women of childbearing potential with a positive urine pregnancy test.

Design outcomes

Primary

MeasureTime frame
Self-Rating Anxiety Scale (SAS);Cambridge Neuropsychological Test Automated Battery;

Secondary

MeasureTime frame
Hamilton Depression Scale (HAMD);Hamilton Anxiety Scale;Self-Rating Depression Scale (SDS);Adverse Event Recording Form;Young Mania Rating Scale (YMRS);Magnetic resonance imaging;Self-Report Questionnaire for Cognitive Deficits;

Countries

China

Contacts

Public ContactZhou Hetong

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

1168600035@zju.edu.cn+86 571 87236114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026